Executive leadership at Greenwich LifeSciences.
Board of directors at Greenwich LifeSciences.
Research analysts covering Greenwich LifeSciences.
Recent press releases and 8-K filings for GLSI.
Greenwich LifeSciences Extends Share Lock-up for Directors and Officers
GLSI
- Greenwich LifeSciences' Board of Directors has extended the lock-up period for shares owned by its directors, officers, and existing pre-IPO investors until September 30, 2026.
- This extension represents an approximately 72-month lock-up from the Company's IPO date, during which these shareholders cannot sell their common stock unless the Board modifies the terms.
- CEO Snehal Patel stated that this 6-year lock-up is designed to align locked-up shareholders with the Company’s long-term investors and to support the FLAMINGO-01 Phase III trial.
- After September 30, 2026, the quantity of these locked-up shares that can be sold will be restricted under a leak-out plan, unless otherwise modified by the Board of Directors.
3 days ago
Greenwich LifeSciences Provides Updates on FLAMINGO-01 Trial and Corporate Strategy
GLSI
New Projects/Investments
Guidance Update
- Greenwich LifeSciences' FLAMINGO-01 Phase III clinical trial is actively enrolling patients at approximately 140 sites, with plans to activate an additional 10 approved sites in 2026 and expand to the United Kingdom and Canada. The Data Safety Monitoring Board (DSMB) recommended continuing the study without modification in December 2025, and the Steering Committee endorsed planned modifications to increase study size and enrollment rate.
- Preliminary analysis of the 250-patient non-HLA-A*02 arm of FLAMINGO-01 shows an approximately 80% reduction in recurrence rate after the Primary Immunization Series, trending similarly to Phase IIb trial results.
- The company's annual burn rate was approximately $7 million in 2024 and 2023, and approximately $7 million for the first three quarters of 2025. ATM financing is being used to manage this burn rate, aiming to reduce the need for near-term financing and increase opportunities for non-dilutive partnerships.
Dec 22, 2025, 11:00 AM
Greenwich LifeSciences Reports Preliminary 80% Recurrence Rate Reduction in FLAMINGO-01 Trial
GLSI
New Projects/Investments
- Greenwich LifeSciences announced a preliminary analysis showing an approximately 80% recurrence rate reduction in the open label non-HLA-A*02 arm of its Phase III clinical trial, FLAMINGO-01.
- This observation, based on 250 fully enrolled patients, is trending similarly to previous Phase IIb trial results where breast cancer recurrences were reduced up to 80%.
- The recurrence rate reduction was estimated using two methods, including a comparison to historical recurrence rates and a comparison of recurrence rates before and after the Primary Immunization Series.
- The company emphasizes that this analysis is preliminary and based on data that is not yet fully reviewed, and future results may differ.
Dec 15, 2025, 11:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more